- Home
- DDOG vs SNY Comparison
DDOG vs SNY Comparison
Compare DDOG & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDOG | SNY |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.7B | 95.7B |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | DDOG | SNY |
|---|---|---|
| Price | $175.41 | $46.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 47 | 11 |
| Target Price | ★ $295.55 | $53.48 |
| AVG Volume (30 Days) | 3.4M | ★ 4.3M |
| Earning Date | 11-04-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 5.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $3,427,158,000.00 | N/A |
| Revenue This Year | $30.57 | $3.80 |
| Revenue Next Year | $22.69 | $5.20 |
| P/E Ratio | $698.96 | ★ $6.14 |
| Revenue Growth | ★ 27.68 | N/A |
| 52 Week Low | $98.01 | $39.07 |
| 52 Week High | $300.68 | $52.68 |
Technical Indicators
Market Signals| Indicator | DDOG | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 77.25 |
| Support Level | $104.32 | $45.87 |
| Resistance Level | $285.75 | $48.78 |
| Average True Range (ATR) | 16.12 | 0.75 |
| MACD | -9.15 | 0.73 |
| Stochastic Oscillator | 2.24 | 99.75 |
Price Performance
Historical ComparisonAbout DDOG Datadog Inc.
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, enables clients to monitor and analyze their entire information technology infrastructure, from servers to applications and Python scripts. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses to ensure uptime and latency objectives.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.